Haart improves prognosis in HIV-associated progressive multifocal leukoencephalopathy

David B. Clifford, C. Yiannoutsos, M. Glicksman, D. M. Simpson, E. J. Singer, P. J. Piliero, C. M. Marra, G. S. Francis, J. C. McArthur, K. L. Tyler, A. C. Tselis, N. E. Hyslop

Research output: Contribution to journalArticlepeer-review

234 Scopus citations


Introduction of highly active antiretroviral therapy (HAART) has been associated with many changes in the complications of human immunodeficiency virus (HIV) infection. A cohort of 25 HIV patients with progressive multifocal leukoencephalopathy (PML) treated with HAART experienced a median survival of >46 weeks. This is an improvement in prognosis compared with recent historic experience and correlated with HIV RNA viral load reductions. We conclude that current HIV therapy is important in improving the outlook of PML in the setting of HIV.

Original languageEnglish
Pages (from-to)623-625
Number of pages3
Issue number3
StatePublished - Feb 1999


Dive into the research topics of 'Haart improves prognosis in HIV-associated progressive multifocal leukoencephalopathy'. Together they form a unique fingerprint.

Cite this